Core Points - The company announced the resignation of Ms. Huang Mengying from various board positions effective December 1, 2025, to focus on decentralized life sciences and expanding her law firm in China [1] - Dr. Yin Huijun has been appointed as a non-executive director effective September 1, 2025 [1] - Ms. Lu Yihsing has been appointed as an independent non-executive director effective September 1, 2025 [1] - Dr. Pan Honghui, the current executive director and CEO, will become the chairman of the board effective December 1, 2025 [1] Board Composition Changes - Dr. Pan has been appointed as the authorized representative effective December 1, 2025 [1] - Mr. Ouyang Yunlong has been appointed as a member of the audit and remuneration committees effective September 1, 2025 [1] - Mr. Wang Yushan has been appointed as a member of the remuneration and investigation committees effective September 1, 2025 [1] - Dr. Zhang Peng has been appointed as the chairman of the remuneration committee effective December 1, 2025, and as a member of the nomination and investigation committees effective September 1, 2025 [1] - Ms. Lu has been appointed as the chairman of the nomination committee effective October 18, 2025, the chairman of the investigation committee effective December 1, 2025, and as a member of the audit committee effective September 1, 2025 [1]
圣诺医药-B：殷惠军获委任为非执行董事